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polymorphism and susceptibility to bladder
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Wei Xu1, Haifeng Zhang2, Fa Wang1 and Honghui Wang1*Abstract
Background: The association between Methylenetetrahydrofolate reductase (MTHFR) Ala222Val (rs1801133) has
been implicated to alter the risk of bladder cancer, but the results are controversial.
Methods: A comprehensive databases of Pubmed, Embase, Web of Science, and the Chinese Biomedical Database
(CBM) were searched for case–control studies investigating the association between MTHFR Ala222Val
polymorphism and bladder cancer susceptibility. Odds ratios (OR) and 95% confidence intervals (95%CI) were used
to assess this possible association. A χ2-based Q-test was used to examine the heterogeneity assumption. Begg’s
and Egger’s test were used to examine the potential publication bias. The leave-one-out sensitivity analysis was
conducted to determine whether our assumptions or decisions have a major effect on the results of the review.
Statistical analysis was performed with the software program Stata 12.0.
Results: A total of 15 independent studies were identified, including 3,570 cases and 3,926 controls. Our analysis
suggested that Ala222Val was not associated with bladder cancer risk in overall population under additive model
(OR=0.96, 95%CI=0.76-1.21, P=0.731), dominant model (OR=1.00, 95%CI=0.87-1.15, P=0.975), recessive model
(OR=0.92, 95%CI=0.79-1.07, P=0.279), and Ala allele versus Val allele (OR=0.96, 95%CI=0.86-1.07, P=0.427). In the
subgroup analysis stratified by ethnicity and sources of controls, there were also no significant associations
detected among different descent populations, population-based studies and hospital-based studies.
Conclusion: This meta-analysis showed the evidence that MTHFR Ala222Val polymorphism was not contributed to
the development of bladder cancer.
Virtual slide: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
2117182849994994.
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Bladder cancer is the second most common genitouri-
nary malignant disease, with an expected 73,510 newly
diagnosed cases and 14,880 deaths in 2012 in America
[1]. Many studies have suggested that several environ-
mental factors such as cigarette smoking, aromatic
amines contained in dyes, chronic inflammation due to* Correspondence: honghuiwang_hlj@163.com
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reproduction in any medium, provided the orinfection, anticancer drugs and radiation are thought to
be risk factors for bladder cancer [2]. However, most in-
dividuals with these known smoking habits, chemical or
environmental exposures never develop bladder cancer
while many bladder cancer cases develop among individ-
uals without those known risk factors, suggesting that
genetic factors also play an important role in bladder
carcinogenesis [3]. Host factors including genetic poly-
morphisms, have been suggested as risk factors for the
development of a variety of cancers, including bladder
cancer.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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methionine synthase (MS) are two enzymes essential for
maintaining folate homeostasis. MTHFR catalyzes the ir-
reversible conversion of 5,10-methylenetetrahydrofolate
to 5-methyltetrahydrofolate, which serves as a substrate
for the remethylation of homocysteine to methionine
with subse-quent synthesis of S-adenosylmethionine
(SAM). Polymorphisms in the methylenetetrahydrofolate
reductase (MTHFR) gene are receiving increasing atten-
tion as variants that may potentially influence methyl
group metabolism and, thereby, alter chromosome integ-
rity. A common Ala222Val variant (an alanine to valine
change) within the N-terminal catalytic domain results
in a thermolabile enzyme with with 35-50% reduced ac-
tivity [4]. Folate deficiency is associated with DNA
strand breakage and uracil misincorporation into DNA
[5]. Thus, if MTHFR polymorphic variants reduce folate
levels by diminishing enzymatic activity, they could en-
hance the propensity for DNA strand breakage and can-
cer occurrence [6]. Alternatively, variant MTHFR
activity could influence the availability of methyl donors
by altering S-adeno-sylmethionine levels, and potentially,
the methylation status of key tumor suppressor or pro-
moter genes involved in bladder carcinogenesis [7]. Fur-
thermore, functional polymorphisms in MTHFR could
affect the metabolism of other carcinogenic substances
that undergo one carbon metabolism such as arsenic
[8,9].
Recently, many studies have investigated the role of
the MTHFR Ala222Val polymorphism in the etiology of
bladder cancer susceptibility. However, the results of
these studies remain inconsistent. Therefore, we
conducted a meta-analysis of all available case–control
studies that have been published to assess the effect of




We conducted a comprehensive search in the Pubmed,
Embase, Web of Science, and Chinese Biomedical Data-
base (CBM) databases updated on March 1, 2013. We
combined search terms for MTHFR Ala222Val poly-
morphism and bladder cancer risk. Search terms in-
cluded: (Methylene-tetrahydrofolate reductase, MTHFR,
Ala222Val, or rs1801133) and bladder cancer. There was
no sample size and language limitation. We evaluated all
associated publications to retrieve the most eligible liter-
atures. All references cited in the included studies were
also hand-searched and reviewed to identify additional
published articles not indexed in common databases. Of
the studies with overlapping data published by the same
authors, only the most recent or complete study was in-
cluded in this meta-analysis.Inclusion and exclusion criteria
Studies included in this meta-analysis had to meet the
following criteria: (1) evaluate the MTHFR Ala222Val
polymorphism and bladder cancer risk, (2) Only the
case–control studies were considered; (3) The paper
should clearly describe the diagnoses of bladder cancer
and the sources of cases and controls; (4) sufficient
reported genotypic frequencies in both cases and con-
trols for estimating an odds ratio (OR) with a 95% confi-
dence interval (95%CI). The exclusion criteria were: (1)
none case–control studies; (2) control population in-
cluding malignant tumor patients; and (3) duplicated
publications.
Data extraction
Information was carefully extracted from all eligible pub-
lications independently by two investigators according to
the selection criteria. In case of disagreement, a third re-
viewer assessed the articles. For each of the eligible
case–control studies, the following data were collected:
the first author’s last name, year of publication, ethnicity,
source of the controls, total number of cases and con-
trols, and genotype distributions in cases and controls.
Quality assessment
Quality assessment of case–control studies in this meta-
analysis was performed using the Newcastle Ottawa
scale (NOS) as recommended by the Cochrane Non-
Randomized Studies Methods Working Group [10]. This
instrument was developed to assess the quality of
nonrandomized studies, specifically cohort and case–
control studies. Based on the NOS, case–control studies
were judged based on three broad perspectives: selection
of study groups (1 criterion), comparability of study
groups (4 criteria), and ascertainment of outcome of
interest (3 criteria). Given the variability in quality of ob-
servational studies found on our initial literature search,
we considered studies that met 5 or more of the NOS
criteria as high quality [10].
Statistical analysis
We examined the association between MTHFR Ala222Val
polymorphism and the bladder cancer risk by calculating
pooled odds ratio (ORs) and 95% confidence intervals
(95%CI). We explored the association between (Ala-
allele vs Val-allele) comparison and bladder cancer de-
velopment, as well as homozygote comparison (Ala/Ala
versus Val/Val), dominant model [(Ala/Ala + Ala/Val)
versus Val/Val)] and recessive model [(Ala/Ala versus
Ala/Val + Val/Val)]. The significance of pooled OR was
tested by Z test. The χ2-based Q-test was also used to
examine the heterogeneity assumption [11]. If studies’
findings only differ by the sampling (P≥0.05), a fixed-
effects model could be used to calculate the combined
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0.05, which suggested that the study results statistically
differ by heterogeneous case and sampling, a random-
effects model could be more suitable. The significance
of the pooled OR was determined by the Z-test, and
P < 0.05 was considered as statistically significant.
The leave-one-out sensitivity analysis was conducted
to determine whether our assumptions or decisions have
a major effect on the results of the review by omitting
each study [12]. Furthermore, subgroup analyses were
performed to test whether the effect size varied by the
ethnicity and the source of control population. To evalu-
ate the published bias, we used Begg’s [13] and Egger’s
[14] formal statistical test and by visual inspection of the
funnel plot. All statistical analyses were performed with
Stata software (version 12.0; Stata Corp LP, College Sta-
tion, TX), using two-sided P values.
Results
Study characteristics
In total, 13 publications including 15 case–control stud-
ies with 3,570 cases and 3,926 controls met the selection
criteria [15-27]. The characteristics of the studies in-
cluded in this meta-analysis are listed in Table 1. Among
the 15 studies, 5 studies of Caucasians, 5 studies of
Asians, 4 studies of Africans and 1 study of mixed popu-
lation, 8 studies of population-based controls, 7 studies
of hospital-based controls. The distribution of the
MTHFR Ala222Val genotype in the control groups of
these 15 studies was all consistent with HWE (All PHWETable 1 Main characteristics of these studies included in this
First author
[Reference]




Kimura [15] 2001 Caucasian 165 150 HB 70
Sanyal [16] 2004 Caucasian 309 246 PB 173
Lin 1 [17] 2004 Caucasian 410 410 PB 176
Moore [18] 2004 Caucasian 106 109 PB 45
Lin 2 [17] 2004 Mixed 17 17 PB 16
Lin 3 [17] 2004 African 21 21 PB 7
Karagas [19] 2005 Caucasian 352 551 PB 140
Moore [20] 2006 Asian 1041 1049 PB 418
Ouerhani [21] 2007 African 111 131 HB 43
Wang [22] 2009 Asian 239 250 PB 66
Ouerhani [23] 2009 African 90 110 HB 33
Rouissi [24] 2009 African 185 191 HB 87
Cai [25] 2009 Asian 312 325 HB 82
Safarinejad [26] 2011 Asian 158 316 HB 67
Izmirli [27] 2011 Asian 54 50 HB 28
HB:Hospital-Based Study. PB: Population-Based Study. HWE: Hardy–Weinberg equilibvalues were more than 0.05, Table 1). According to the
quality criteria, all the 15 studies were high quality.
Quantitative synthesis
Overall, there was no association between bladder can-
cer risk and the variant genotypes in different genetic
models when all the eligible studies were pooled into the
meta-analysis. As show in Table 2, compared with the
wild-type homozygote genotype, the homozygote variant
genotype Val/Val was not associated with a statistically
significant increase risk of bladder cancer (OR=0.96,
95%CI=0.76-1.21, P=0.73, Figure 1). Simultaneously, no
significant effects were observed in dominant (OR=1.00,
95%CI=0.87-1.47, P=0.96, Figure 2), recessive models
(OR=0.92, 95%CI=0.79-1.07, P=0.28, Figure 3), and Ala
allele vs Val allele comparison model (OR=0.96, 95%
CI=0.86-1.07, P=0.43, Figure 4). When we analyzed the
relationship of MTHFR Ala222Val polymorphism and
bladder cancer risk in different ethnicity subgroup, our
data showed that this polymorphism did not contribute
to the bladder cancer risk among different descent
populations. Subgroup analyses were also performed
according to the source of control population. We didn’t
observe any significant association both population-
based study and hospital-based study in any genetic
model using random effect model (Table 2).
Sensitivity analysis
In order to compare the sensitivity of this meta-analysis,
we conducted a leave-one-out sensitivity analysis. Ameta-analysis
Cases Controls HWE
Ala/Val Val/Val Ala/Ala Ala/Val Val/Val
80 15 65 73 12 0.17
113 23 121 102 23 0.82
183 51 196 164 50 0.09
42 19 32 59 18 0.29
1 0 13 4 0 0.58
13 1 9 9 3 0.76
171 39 227 245 71 0.70
478 145 402 486 161 0.48
58 10 58 56 17 0.55
129 45 88 132 30 0.07
50 7 51 45 14 0.42
86 12 81 90 20 0.49
169 61 113 170 42 0.08
74 17 144 142 30 0.56
22 4 36 14 0 0.25
rium. 1,2,3: Different descent populations in one publication.
Table 2 Meta-analysis on the association between MTHFR Ala222Val polymorphism and bladder cancer risk
Variables Study number Sample size Test of heterogeneity Test of Association
case control Ph I
2 OR(95% CL) P
Ala/Ala vs Val/Val
Total 15 3570 3926 0.04 44.3% 0.96 (0.76 1.21) 0.73
Ethnicity
Caucasian 5 1342 1466 0.70 0.0% 1.07 (0.83 1.38) 0.59
Asian 5 1804 1990 0.00 74.3% 0.68 (0.41 1.12) 0.13
African 4 407 453 0.91 0.0% 1.50 (0.91 2.45) 0.11
Mixed population 1 17 17 — — — —
Source of control
HB 7 1075 1273 0.07 49.3% 0.90 (0.58 1.39) 0.62
PB 8 2495 2653 0.14 37.5% 1.20 (0.79 1.31) 0.88
Ala/Ala vs Ala/Val
Total 15 3570 3926 0.05 41.3% 0.92 (0.80 1.06) 0.24
Ethnicity
Caucasian 5 1342 1466 0.05 58.9% 1.05 (0.81 1.37) 0.70
Asian 5 1804 1990 0.15 40.4% 0.86 (0.69 1.06) 0.15
African 4 407 453 0.26 25.9% 0.80 (0.56 1.13) 0.20
Mixed population 1 17 17 — — 4.92 (0.49 49.61) 0.18
Source of control
HB 7 1075 1273 0.40 3.7% 0.82 (0.68 0.98) 0.03
PB 8 2495 2653 0.04 51.5% 1.01 (0.82 1.23) 0.94
Ala/Val vs Val/Val
Total 15 3570 3926 0.22 21.5% 1.02 (0.85 1.23) 0.81
Ethnicity
Caucasian 5 1342 1466 0.69 0.0% 1.07 (0.83 1.37) 0.60
Asian 5 1804 1990 0.18 36.0% 0.84 (0.63 1.12) 0.24
African 4 407 453 0.86 0.0% 1.86 (1.14 3.03) 0.01
Mixed population 1 17 17 — — — —
Source of control
HB 7 1075 1273 0.14 38.6% 1.08 (0.73 1.59) 0.71
PB 8 2495 2653 0.35 10.7% 1.03 (0.85 1.25) 0.76
Dominant model
Total 15 3570 3926 0.12 32.3% 1.00 (0.87 1.15) 0.98
Ethnicity
Caucasian 5 1342 1466 0.86 0.0% 1.07 (0.84 1.35) 0.58
Asian 5 1804 1990 0.03 63.4% 0.77 (0.52 1.12) 0.17
African 4 407 453 0.94 0.0% 1.68 (1.05 2.69) 0.03
Mixed population 1 17 17 — — — —
Source of control
HB 7 1075 1273 0.09 46.0% 1.00 (0.67 1.49) 0.99
PB 8 2495 2653 0.29 18.4% 1.03 (0.84 1.25) 0.80
Recessive model
Total 15 3570 3926 0.02 49.1% 0.92 (0.79 1.07) 0.28
Ethnicity
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Table 2 Meta-analysis on the association between MTHFR Ala222Val polymorphism and bladder cancer risk (Continued)
Caucasian 5 1342 1466 0.07 54.4% 1.06 (0.83 1.34) 0.66
Asian 5 1804 1990 0.02 67.0% 0.79 (0.60 1.04) 0.09
African 4 407 453 0.33 12.9% 0.90 (0.67 1.21) 0.49
Mixed population 1 17 17 — — 4.92 (0.49 49.61) 0.18
Source of control
HB 7 1075 1273 0.20 29.8% 0.92 (0.66 1.01) 0.06
PB 8 2495 2653 0.04 53.5% 1.01 (0.83 1.23) 0.90
Ala-allele vs Val-allele
Total 15 3570 3926 0.01 50.5% 0.96 (0.86 1.07) 0.43
Ethnicity
Caucasian 5 1342 1466 0.26 23.8% 1.03 (0.90 1.18) 0.66
Asian 5 1804 1990 0.00 76.5% 0.81 (0.65 1.03) 0.08
African 4 407 453 0.65 0.0% 1.05 (0.86 1.29) 0.63
Mixed population 1 17 17 — — 4.40 (0.47 41.60) 0.20
Source of control
HB 7 1075 1273 0.07 48.0% 0.89 (0.74 1.06) 0.19
PB 8 2495 2653 0.07 47.3% 1.01 (0.89 1.15) 0.89
HB Hospital-Based Study, PB Population-Based Study, Ph P value of heterogeneit.
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each time to reflect the influence of the individual data
set to pooled ORs. The results pattern was not impacted
by single study in all genetic models, for example, under
the allele contrast model (Ala versus Val) was shown in
Figure 5. The P for Q test and the I2 value also showedFigure 1 Forest plots for MTHFR Ala222Val polymorphism and risk ofthat none of single study affected the heterogeneity of
this meta-analysis.
Publication bias
Begg’s funnel plot and Egger’s test were used to as-
sess the publication bias in this meta-analysis. Thebladder cancer in overall populations (Ala/Ala versus Val/Val).
Figure 2 Forest plots for MTHFR Ala222Val polymorphism and risk of bladder cancer in overall populations (Dominant model).
Figure 3 Forest plots for MTHFR Ala222Val polymorphism and risk of bladder cancer in overall populations (Recessive model).
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Figure 4 Forest plots for MTHFR Ala222Val polymorphism and risk of bladder cancer in overall populations (Ala allele vs Val allele).
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http://www.diagnosticpathology.org/content/8/1/95Funnel plots’ shape of all contrasts did not reveal ob-
vious evidence of asymmetry, and all the P values of
Egger’s test were more than 0.05, providing statistical
evidence for the funnel plots’ symmetry. For example,
this meta-analysis investigated the association between
MTHFR Ala222Val polymorphism and bladder cancerFigure 5 Sensitive analysis for the MFHTR Ala222Val polymorphism il
vs Val allele).under the allele contrast model (Ala versus Val).
Begg’s test for the allele contrast model was shown in
Figure 6, and Egger’s test for the allele contrast
model was shown in Figure 7. Thus, the above results
suggest that publication bias was not evident in this
meta-analysis.lustrating the influence of each studies on pooled OR (Ala- allele
Figure 6 Begg’s funnel plot for assessing the publication bias under the allele contrast model (Ala allele vs. Val allele).
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It is wide acknowledged that genetics play an important
role in determining cancer risk and association studies
have been identified to evaluate cancer susceptibility
[28]. However, many associated studies failed to pro-
vide convincing evidence of linkage and resulted in
contradicting findings. Meta-analysis provided a popu-
lar method for combining world literatures across stud-
ies to resolve the statistical power and discrepancy
problem in associate studies [29]. It was more system-
atic for its statistical methods than single case–control
studies and cohort studies [30-32].
Previous epidemiological studies have evaluated the
association between bladder cancer risk and MTHFR
Ala222Val polymorphism, but with inconclusive re-
sults. An initial cohort study suggested a 5.5 fold riskFigure 7 Egger’s funnel plot for assessing the publication bias underof bladder and kidney cancer combined among 222
Ala>Val variant homozygotes [33]. In contrast, three
case–control studies provided the evidence that there
was no overall association of MTHFR Ala222Val geno-
type with bladder cancer [15-17], one study observed a
reduced risk among heterozygotes for MTHFR
Ala222val [18].
Based on 15 studies providing data on MTHFR
Ala222Val polymorphism and bladder cancer risk, we
conduced a meta-analysis involving in 3,570 cases and
3,926 controls to indicate if this polymorphism was sig-
nificantly associated with bladder cancer risk. Moreover,
we also evaluated the publication bias. The MTHFR
Ala222Val genotypes funnel plot was approximately
symmetrical. Furthermore, Begg’s and Eggle’s test
showed that there was no publication bias in this study.the allele contrast model (Ala allele vs. Val allele).
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tween this polymorphism and bladder cancer risk in the
all genetic models. These results suggested that the
MTHFR Ala222Val polymorphism might be not contrib-
uted to the development of bladder cancer. It has been
well known that cancer occurrence and mortality varied
by ethnicity and geographic location [34]. In this meta-
analysis, all subjects were sub-grouped into four groups
(Caucasian, Asian, African and mixed populations). No
association of Ala222Val polymorphism with bladder
cancer risk was detected in different descent popula-
tions. When stratified by source of controls, the similar
results were found both in population-based and
hospital-based studies.
Some limitations of our meta-analysis should be
addressed. Firstly, the numbers of published studies
collected in our analysis were not large enough for the
comprehensive analysis. Secondly, lacking the original
data of the included studies limited our study to fur-
ther evaluate the potential interactions, since gene-
environment and gene-gene interactions may modulate
bladder cancer risk. So, a more precise analysis needs
to be conducted if individual data such as age and sex
are available. Nevertheless, advantages in our meta-
analysis should also be acknowledged. A systematic re-
view of the association of MTHFR Ala222Val poly-
morphism with bladder cancer risk is statistically more
powerful than any single study. Furthermore, the stud-
ies included in our meta-analysis strictly and satisfac-
tory met our selection criteria.
Conclusions
In conclusion, our meta-analysis provided the evidence
that the MTHFR Ala222Val polymorphism maybe not
contributed to the development of bladder cancer. In
addition, further studies with larger sample sizes and
careful design are needed to identify this association
more comprehensively.
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